Haemophagocytic syndrome after intravesical bacille Calmette-Guérin instillation.
Abstract Intravesical bacille Calmette-Guérin (BCG) is used to treat high-risk superficial bladder cancer. This article reports a case of secondary haemophagocytosis after intravesical BCG instillation in a 70-year-old man with bladder cancer and presents a literature review of this very rare but potentially fatal complication of intravesical BCG treatment.
1Department of Urology, Princess Royal Hospital, Brighton & Sussex University Hospitals NHS Trust , Haywards Heath , UK.
Saumya
S
Misra
Amit
A
Gupta
Andrew
A
Symes
John
J
Duncan
D000276:Adjuvants, Immunologic / Q000009:adverse effects*; D000283:Administration, Intravesical; D000368:Aged; D001500:BCG Vaccine / Q000009:adverse effects*; D001853:Bone Marrow / Q000473:pathology; D002278:Carcinoma in Situ / Q000188:drug therapy*; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy*; D006801:Humans; D051359:Lymphohistiocytosis, Hemophagocytic / Q000139:chemically induced* / Q000473:pathology; D008297:Male; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy*
D000276:Adjuvants, Immunologic; D001500:BCG Vaccine
BCG; haemophagocytosis; intravesical